The FDA Oncologic Drugs Advisory Committee and the Cellular, Tissue and Gene Therapies Advisory Committee will jointly review talimogene laherparepvec for the treatment of patients with injectable regionally or distantly metastatic melanoma at a meeting April 29.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
